Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Atrial Fibrillation
and you are
between 18 and 85
years old
3
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

The aim of the study is to find out whether aliskiren reduces atrial fibrillation burden measured with a pacemaker device

Provided treatments

  • Drug: aliskiren
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02909166. The sponsor of the trial is Mika Lehto and it is looking for 70 volunteers for the current phase.
Official trial title:
Role of ALiskiren, a Direct Renin Inhibitor, in Preventing Atrial Fibrillation in Patients With a Pacemaker; RALF. A Double-blind, Randomized, Parallel-group, Single Centre Study